Bayer's Calendar Tightens: A Japan Oncology Approval and a Rescheduled Glyphosas Hearing Define the Next Fortnight

Bayer gains legal edge from Supreme Court ruling, delays Roundup settlement hearing to Sept 14, and wins Japan approval for lung cancer drug Sevabertinib.

The next two weeks will tell investors a great deal about how Bayer's two most consequential narratives—the legal overhang from Roundup and the commercial promise of its drug pipeline—are likely to resolve. On one side of the ledger sits a freshly granted regulatory green light in Japan; on the other, a court hearing that keeps slipping, now set for 14 September, roughly three weeks later than originally planned.

That hearing, which concerns the final approval of the multi-billion-euro glyphosate settlement, was pushed back from 19 August at the joint request of Bayer and the plaintiffs' bar. The reasoning is straightforward: the extra time allows claimants who had opted out of the €6.3 billion class settlement to reconsider and revoke that decision. Each plaintiff who stays in the deal reduces the uncertainty around Bayer's residual financial exposure, making the company's risk profile more predictable for shareholders.

A Supreme Court Tailwind

The rescheduling follows a significant legal victory that has shifted the terrain in Bayer's favor. Late June saw the US Supreme Court rule 7-2 that federal law preempts state-level failure-to-warn claims against Roundup, citing the primacy of EPA approval requirements over individual state statutes. That decision strips the legal foundation from thousands of pending cases alleging inadequate cancer warnings, handing Bayer a strategic advantage as it approaches the September hearing.

The company is also repositioning its US operations to match the new legal and commercial reality. Early July brought the creation of Ruveon, a St. Louis-based subsidiary that consolidates Bayer's American glyphosate business. While Ruveon remains wholly owned by the parent, it now handles pricing, production, and logistics independently—a structure designed to respond more nimbly to US market dynamics.

The Pipeline Counterweight

On the pharmaceutical front, Bayer secured approval from Japanese regulators for Sevabertinib, marketed there as Hyrnuo, as a treatment for HER2-mutated unresectable non-small cell lung cancer. The Tuesday announcement confirmed and fleshed out a preliminary approval flagged the previous day, underscoring the company's push into oncology as a growth pillar.

For a firm long weighed down by litigation costs and balance-sheet pressure, the Japan approval offers a tangible demonstration that R&D momentum remains intact despite the financial drag from the US legal battles. It also reinforces the narrative that Bayer can navigate regulatory hurdles in major healthcare markets even as it manages legacy liabilities.

Numbers That Support the Story

The operational backdrop for these developments is a set of second-quarter figures that came in ahead of expectations. Adjusted group revenue rose 2.2 percent to €10.872 billion, while EBITDA before special items gained 1.9 percent to €2.144 billion. Crop Science delivered a standout performance with EBITDA up 30.2 percent to €902 million, though core earnings per share slipped 16.7 percent to €0.95.

Management held its full-year guidance steady, reiterating a revenue corridor of €44.7 billion to €46.7 billion and core EPS of €4.20 to €4.70. More striking, however, was the revision to the deleveraging trajectory: net financial debt is now expected to end 2026 at €29–30 billion, down from the previously communicated €32–33 billion. That improvement reflects the €3.0 billion capital injection from Apollo, agreed in July, in exchange for a minority stake in the long-acting reversible contraception (LARC) business—a deal in which Bayer retains both majority ownership and operational control.

Reading the Tape

The equity market has taken a measured view. The shares, which last traded at €48.98, sit roughly 19 percent above their 200-day moving average of €41.11, suggesting the medium-term uptrend remains intact despite a recent session that closed 0.6 percent lower. The stock also holds comfortably above its shorter-term moving averages, a sign of persistent buying interest.

Yet the price remains about nine percent below its 52-week high of €53.86, a gap that hints at lingering caution. Investors appear to be waiting for clarity on how many plaintiffs ultimately remain in the settlement before committing fully to the re-rating story.

A separate regulatory development—a non-binding statement from Germany's Federal Cartel Office regarding the so-called 50+1 rule—adds another thread to the administrative web surrounding the company, though it carries no immediate legal force.

For now, the September 14 hearing stands as the pivotal near-term catalyst. If Bayer can further shrink the opt-out pool, it would mark another step toward making its legal exposure calculable—and, alongside the improving debt picture, give the bulls one more concrete argument to work with.